Skip to main content
Premium Trial:

Request an Annual Quote

Ventana, Boehringer Ingelheim to Collaborate on CDx for Cancer Drugs

NEW YORK (GenomeWeb News) – Ventana Medical Systems and Boehringer Ingelheim announced today that they will collaborate on the development of companion diagnostic products for cancer drugs in the German drug firm's pipeline.

Ventana plans to utilize its immunohistochemistry technology platform and its experience in companion diagnostic development and premarket approval submissions to support Boehringer Ingelheim's personalized medicine strategies for cancer drug development, the firms said. The partners didn't name specific drug candidates or types of cancers that would be targeted by the collaboration.

Further terms of the alliance also were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.